NCT07746323 Effect of Modified Arm Positioning on Shoulder Pain After Thoracoscopic Lobectomy
| NCT ID | NCT07746323 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chengdu Jinjiang Maternity and Child Health Hospital |
| Condition | Ipsilateral Shoulder Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 270 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 270 participants in total. It began in 2026-05-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective randomized controlled trial aiming to reduce shoulder pain after lung surgery. Shoulder pain on the surgical side is common after video-assisted thoracoscopic lobectomy, affecting about 20%-58% of patients. It can limit coughing, moving, and sleeping, and may delay recovery. The pain may come from two sources: nerve stimulation during surgery and the prolonged arm position used during the operation. While nerve stimulation is hard to avoid, the arm position can be modified. Currently, most pain treatments rely on medications or nerve blocks given after surgery, which have side effects or risks. No one has tried to prevent the pain by changing the arm position during the operation. We plan to enroll 270 patients scheduled for thoracoscopic lung removal surgery at Chengdu Shangjin Nanfu Hospital. Patients will be randomly divided into two groups. One group will receive the standard side-lying position with arms extended on arm boards (traditional position). The other group will receive a modified position where both arms are bent at the elbows and wrapped with surgical drapes, without using arm boards (modified double-arm wrap position). Our main goal is to compare the rate of shoulder pain (on the operated side) within 24 hours after surgery between the two groups. We will also compare pain on the opposite shoulder, pain severity, time needed to set up the position, total surgery time, hospital stay, and any nerve or skin complications. This study has been approved by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University. All participants will provide written informed consent. The findings may help improve intraoperative positioning and enhance early recovery after lung surgery.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Diagnosed with pulmonary space-occupying lesion and scheduled for elective video-assisted thoracoscopic standard lobectomy. 3. ASA physical status classification I-III. 4. No pre-existing shoulder pain or shoulder mobility impairment prior to surgery. 5. No long-term use of analgesic medications (\>1 week) before surgery. 6. Willing and able to provide written informed consent. Exclusion Criteria: 1. Severe cervical spine disease or history of brachial plexus injury. 2. Cognitive impairment or psychiatric disorder precluding understanding of pain assessment scales.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07746323 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ipsilateral Shoulder Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07746323 currently recruiting?
Yes, NCT07746323 is actively recruiting participants. Contact the research team at fengluhx@163.com for enrollment information.
Where is the NCT07746323 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT07746323 clinical trial?
NCT07746323 is sponsored by Chengdu Jinjiang Maternity and Child Health Hospital. The trial plans to enroll 270 participants.